Indolent T-Cell Non-Hodgkin Lymphoma — Trials

Indolent T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

134 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: City of Hope Medical Center
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05944562	Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome	active not recruiting	Phase 1	24	Washington University School of MedicineOTHER	1	Sep 16, 2026	clinicaltrials
NCT02520791	Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma	active not recruiting	Phase 1	21	National Cancer Institute (NCI)NIH	2	Jun 26, 2026